Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-07-20 09:25 UTC (UTC+2h)

General BE topics [Design Issues]

posted by VSL - India, 2017-06-05 18:34  - Posting: # 17444
Views: 6,477

Dear all,
Could you please give your views on the following topics?
  1. Half-life: Is half life independent of formulation effect? I mean, IR vs. MR products of the same substance. I am asking as protocol design depends a lot on it.
  2. High variable drug substance vs. High variable drug products, Is there is any demarcation for protocol design aspects?
  3. If there are two strengths, say, tablet, 10 and 20 mg and 20 mg is RLD. The company wishes to market only 10 mg strength but 10 mg is not RLD. What should be RLD in BE study? Is comparison of 10mg x2 tablets (test) vs. 20mg RLD right?
  4. What is the minimum sample size for parallel group BE study?
  5. For endogenous substances, how many and for how much time duration (-48 hours etc.) baseline samples should be collected?
  6. Why passing ratio is high for BE studies (especially pivotal studies) conducted in India compared to foreign countries? Is there any geographical/ethnic/staff expertise/deliberate effect?
  7. For some therapeutic class drugs BE study, I have not seen any PD effect. Example, For Antihypertensive drugs, no change in BP in vital recordings even at/around Cmax. Please explain.

Thanks and Regards,

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,547 posts in 3,941 threads, 1,192 registered users;
online 21 (1 registered, 20 guests [including 16 identified bots]).

If there is an exception to any rule,
and if it can be proved by observation,
that rule is wrong.    Richard Feynman

BEBAC Ing. Helmut Schütz